HKD
AMTD Digital Inc - ADR
-24.37%
$9.48 - $7.17
Feb 8th 2023 - Mar 22nd 2023
Jan, 5, 2023
I’m sure patient will rewards high.
Nov, 11, 2022
$HKD I wonder how long they will hold it I’m super... See more
XERS
Xeris Biopharma Holdings Inc
15.52%
$1.16 - $1.34
Feb 7th 2023 - Mar 21st 2023
Jan, 12, 2023
$XERS On Gvoke, "better than expected growth&... See more
Nov, 4, 2022
QoQ growth would still increase by ~40% with no new patients.
Jan, 5, 2023
I’m sure patient will rewards high.
Nov, 11, 2022
$HKD I wonder how long they will hold it I’m super patient I will be holding & adding more by days I’m not leaving 😂 soon or later it will eventually explode 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
Feb, 1, 2023
$PALI patients ⏰⏰⏰
Jan, 23, 2023
$PALI patients are in high gear 🤑🤑🤑
Oct, 5, 2022
Conclusion: For patients undergoing elective bowel resection surgery, LB1148 was safe and well-tolerated and significantly accelerated the return of bowel function.
Jan, 12, 2023
$XERS On Gvoke, "better than expected growth": "Opportunity remains huge, and you don't have to find patients.
Nov, 4, 2022
QoQ growth would still increase by ~40% with no new patients.
Oct, 20, 2022
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Oct, 20, 2022
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Oct, 20, 2022
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Oct, 20, 2022
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Oct, 20, 2022
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Oct, 20, 2022
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Oct, 20, 2022
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.